Monoclonal antibody neutralizes <i>Staphylococcus aureus</i> serine protease-like protein B (SplB)-induced pathology.

ABSTRACT: Staphylococcus aureus is a versatile pathogen, renowned for its arsenal of virulence and immune evasion factors. Several S. aureus virulence factors have been targeted in vaccination trials; however, so far, without success. Promising new vaccine candidates are the staphylococcal serine protease-like proteins (Spl A-F), which are involved in the pathogenesis and immune evasion of S. aureus. SplB, for instance, promotes type 2 immune responses and inactivates human complement factors. In this study, we report on the production and characterization of a murine monoclonal antibody (mAb) against SplB. The murine anti-SplB mAb α-SplB1 was produced by hybridoma technology, and its binding characteristics were investigated using enzyme-linked immunosorbent assay (ELISA), West

SUBMITTER: Iqbal J 

PROVIDER: S-EPMC12234435 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature